iOnctura brings together several key advantages that position it to efficiently explore novel and rational combination therapies. Our collaborations with Merck KGaA and Cancer Research UK allows us to advance these potential therapies quickly to cancer patients.
- Merck KGaA, Darmstadt, Germany will provide iOnctura with clinical supply of avelumab* for early clinical combination studies.
- Cancer Research UK will provide research and development expertise and infrastructure through their highly respected Therapeutic Discovery laboratories (CRUK-TDL) and provide access to a broad network of academic collaborators.
*Avelumab is jointly developed by Merck KGaA, Darmstadt, Germany and Pfizer.
Please scroll down to read more about Merck KGaA, Darmstadt, Germany and Cancer Research UK.
Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Their specialist Commercial Partnerships Team work closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. The team develop promising ideas into successful cancer therapeutics, software, devices, diagnostics and enabling technologies. This helps to accelerate progress in exciting new discoveries in cancer research and bring new treatments to patients sooner. More information on Cancer Research UK’s Commercial Partnerships Team can be found at http://commercial.cancerresearchuk.org/
Cancer Research UK’s Therapeutic Discovery Laboratories (CRUK-TDL) is the in-house Cancer Research UK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. Their expertise spans cancer target validation and disease positioning, immunology, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through their alliance approach, they align these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit. More information on CRUK-TDL can be found at http://discoverylabs.cancerresearchuk.org
For more information about other areas of Cancer Research UK see: https://www.cancerresearchuk.org
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries. Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the “Merck” name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.